Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 pen injector bioequivalence study in healthy males
NCT05681845Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of denecimig in hemophilia A (4 arms), sponsored by Novo Nordisk. Primary endpoints: Area Under the Mim8 Plasma Concentration-Time Curve from Time 0 Until 112 Days After a Single Dose and Maximum Plasma Concentration of Mim8 After a Single Dose at 113 days. Started Jan 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05681845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681845.